Evidence map›Paper›PMID 32095558›Full record

ArticleTechnical innovations & patient support in radiation oncology2017

Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity.

Agnieszka Lemanska, Rachel C Byford, Ana Correa, Clare Cruickshank, David P Dearnaley, Clare Griffin, Emma Hall, Simon de Lusignan, Sara Faithfull

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technical innovations & patient support in radiation oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Agnieszka LemanskaSchool of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Rachel C ByfordDepartment of Health Care Management and Policy, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Ana CorreaDepartment of Health Care Management and Policy, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Clare CruickshankThe Institute of Cancer Research - Clinical Trials and Statistics Unit, London, UK.
David P DearnaleyThe Institute of Cancer Research and Royal Marsden NHS Trust, London, UK.
Clare GriffinThe Institute of Cancer Research - Clinical Trials and Statistics Unit, London, UK.
Emma HallThe Institute of Cancer Research - Clinical Trials and Statistics Unit, London, UK.
Simon de LusignanDepartment of Health Care Management and Policy, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Sara FaithfullSchool of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
University of Surrey · GBInstitute of Cancer Research · GB

Funding

Cancer Research UK 7253
6 · The paper itself

Abstract

backgroundPatients receiving cancer treatment often have one or more co-morbid conditions that are treated pharmacologically. Co-morbidities are recorded in clinical trials usually only at baseline. However, co-morbidities evolve and new ones emerge during cancer treatment. The interaction between multi-morbidity and cancer recovery is significant but poorly understood. PURPOSE: To investigate the effect of co-morbidities (e.g. cardiovascular and diabetes) and medications (e.g. statins, antihypertensives, metformin) on radiotherapy-related toxicity and long-term symptoms in order to identify potential risk factors. The possible protective effect of medications such as statins or antihypertensives in reducing radiotherapy-related toxicity will also be explored.

methodsTwo datasets will be linked. (1) CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer) randomised control trial. CHHiP contains pelvic symptoms and radiation-related toxicity reported by patients and clinicians. (2) GP (General Practice) data from RCGP RSC (Royal College of General Practitioners Research and Surveillance Centre). The GP records of CHHiP patients will be extracted, including cardiovascular co-morbidities, diabetes and prescription medications. Statistical analysis of the combined dataset will be performed in order to investigate the effect.

conclusionsLinking two sources of healthcare data is an exciting area of big healthcare data research. With limited data in clinical trials (not all clinical trials collect information on co-morbidities or medications) and limited lengths of follow-up, linking different sources of information is increasingly needed to investigate long-term outcomes. With increasing pressures to collect detailed information in clinical trials (e.g. co-morbidities, medications), linkage to routinely collected data offers the potential to support efficient conduct of clinical trials.

Indexed as

ANOVA, analysis of varianceBig dataBNF, British National FormularyCHHiPCHHiP, Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate CancerData linkageEPIC, Expanded Prostate Cancer Index CompositeFACT-P, Functional Assessment of Cancer Therapy-ProstateGEE, Generalized Estimating EquationsGP, General PractitionerICD10, International Classification of Disease version 10ICR, Institute of Cancer ResearchIMRT, Intensity Modulated RadiotherapyLate-effectsLENT/SOMA, Late Effects Normal Tissue Toxicity; subjective, objective, management, and analyticPCa, Prostate cancerPROs, Patient Reported OutcomesQOL, Quality of lifeRadiotherapy-related side-effectsRCGP, Royal College of General PractitionersRCGP RSCRCT, Randomised Control TrialREC, Research Ethics CommitteeRSC, Research & Surveillance CentreRTOG, Radiation Therapy Oncology GroupSHA2-512, Secure Hash Algorithm 2 with 512 bit hash valuesUCLA-PCI, University of California, Los Angeles Prostate Cancer IndexUK, United Kingdom

Identifiers

PMID32095558
PMCPMC7033766
OpenAlexW2622076966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.